Vertebral Metastasis Treated by Vertebroplasty, a Cause of Respiratory Failure: Case Report and Literature Review.
Bone metastasis
Lung cancer
Vertebroplasty
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
27
11
2020
accepted:
27
11
2020
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
Bone is a frequent site of metastases in advanced cancers including lung, breast, prostate, kidney, or myeloma. Lesions are commonly located on the spine. Neoplastic invasion of the vertebral body can result in painful vertebral fractures, leading to disability and substantial morbidity. Percutaneous vertebroplasty is a minimally invasive surgical procedure used to treat spinal fractures due to osteolytic tumors. It could result in pain reduction or resolution in 80-90% of patients with fractures, and it improves stability. Although considered safe, vertebroplasty has been associated over the years with life-threatening complications. We have reported the case of a 55-year-old patient with lung adenocarcinoma, who underwent vertebroplasty for a pathological neoplastic fracture of L2. The procedure was complicated by a leak of cement into the systemic venous circulation, characterized by an 11-cm filament in the right heart chambers and multiple pulmonary emboli. To our knowledge, only one similar case was previously reported, involving an intracardiac cement filament longer than 10 cm. The data are scant, hence the importance of collecting and reporting possible complications about what is perceived as a rather safe procedure. The case highlights the need for a robust postprocedure imaging plan to detect complications, which can impact patients' morbidity and survival.
Identifiants
pubmed: 33776717
doi: 10.1159/000513492
pii: cro-0014-0279
pmc: PMC7983615
doi:
Types de publication
Case Reports
Langues
eng
Pagination
279-283Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to disclose.
Références
Lancet. 2010 Sep 25;376(9746):1085-92
pubmed: 20701962
Clin Lung Cancer. 2020 Nov;21(6):e539-e543
pubmed: 32499210
Lancet Oncol. 2011 Mar;12(3):225-35
pubmed: 21333599
Oncol Rev. 2017 May 09;11(1):321
pubmed: 28584570
Semin Intervent Radiol. 2007 Dec;24(4):409-18
pubmed: 21326593
Age Ageing. 2012 Jul;41(4):450-5
pubmed: 22417981
Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):577-582
pubmed: 31659111
Clin Radiol. 2011 Jan;66(1):63-72
pubmed: 21147301
Cancer Treat Rev. 2020 Apr;85:101978
pubmed: 32062493
Eur Rev Med Pharmacol Sci. 2007 Mar-Apr;11(2):91-100
pubmed: 17552138
Acta Radiol Open. 2015 Aug 07;4(8):2058460115595660
pubmed: 26331092
Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):597-603
pubmed: 32859638